Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;12(10):2755-2766.
doi: 10.1007/s13300-021-01146-3. Epub 2021 Sep 7.

The Association Between Mean Glycated Haemoglobin or Glycaemic Variability and the Development of Retinopathy in People with Diabetes: A Retrospective Observational Cohort Study

Ketan Dhatariya  1   2 , Alexander Humberstone #  3 , Abul Hasnat #  3 , Rebecca Wright #  3 , Morgan Lujan #  3 , Ian Nunney  4
Affiliations

The Association Between Mean Glycated Haemoglobin or Glycaemic Variability and the Development of Retinopathy in People with Diabetes: A Retrospective Observational Cohort Study

Ketan Dhatariya et al. Diabetes Ther. 2021 Oct.

Abstract

Introduction: To determine the association between mean glycated haemoglobin (HbA1c) or glycaemic variability and the development of diabetic retinopathy (DR) in people with diabetes.

Methods: An observational cohort study with people registered with a DR eye screening service between October 2012 and October 2017. Those who had no DR at the start of the study were followed for a maximum of 5 years. HbA1c measures were used to calculate HbA1c variability and mean HbA1c to assess any relationship between these and the risk of developing new onset DR.

Results: A total of 2511 individuals were followed up for up to 5 years. Of these, 542 (21.6%) developed DR. After adjustment, HbA1c variability was not significantly associated with the development of DR (p = 0.3435). However, the mean HbA1c was (p < 0.0001). Those with type 1 diabetes had an odds of 1.63 (95% CI 1.11-2.40) of a retinopathy diagnosis compared to those with type 2 diabetes.

Conclusions: We have shown that mean HbA1c is associated with an increased risk of developing diabetic retinopathy. However, after adjustment for sex, age, diabetes type and the mean, the HbA1c variability no longer remained significant. Our data suggest that optimizing long-term glycaemic control remains paramount.

Keywords: Diabetic retinopathy; Glycaemic variability; HbA1c; Risk.

Plain language summary

It has been known for a long time that if an individual’s diabetes is not as well controlled as it could be, then they are at increased risk of developing complications over many years. These complications include diabetes-related eye disease (retinopathy). For many years, the way of measuring how well someone’s diabetes was controlled was by measuring glycated haemoglobin (HbA1c) which looked at how much glucose was attached to a red cell. This study looked at whether variation in HbA1c over 5 years of follow-up was associated with greater risk of developing retinopathy, and if this relationship was stronger than just measuring HbA1c alone. Previous work has shown that people with greater variation in HbA1c are at increased risk of poor wound healing in those with diabetes-related foot ulcers. The present study looked at 2511 people who had no diabetes-related eye disease at the start of the study and who had been followed for 5 years. We found that variability in HbA1c was not associated with an increased risk of developing diabetes-related eye disease, but confirmed that the average HbA1c had the strongest relationship. Our data confirm that the focus of preventing diabetes-related eye disease should be on lowering HbA1c.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
CONSORT diagram for the subjects in the study
See this image and copyright information in PMC

References

    1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124–136. doi: 10.1016/S0140-6736(09)62124-3. - DOI - PubMed
    1. Quartilho A, Simkiss P, Zekite A, et al. Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013. Eye. 2016;30:602–607. doi: 10.1038/eye.2015.288. - DOI - PMC - PubMed
    1. Sabanayagam C, Banu R, Chee ML, et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol. 2019;7:140–149. doi: 10.1016/S2213-8587(18)30128-1. - DOI - PubMed
    1. Leasher JL, Bourne RR, Flaxman SR, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care. 2016;39:1643–1649. doi: 10.2337/dc15-2171. - DOI - PubMed
    1. Kramer CK, Rodrigues TC, Canani LH, Gross JL, Azevedo MJ. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes. Diabetes Care. 2011;34:1238–1244. doi: 10.2337/dc11-0079. - DOI - PMC - PubMed

LinkOut - more resources